PURPOSE: The Epic End of Life Care Index (EOLCI) predicts 1-year mortality for a general adult population using medical record data. It is deployed at various medical centers, but we are not aware of an independent validation. We evaluated its performance for predicting 1-year mortality in patients with metastatic cancer, comparing it against an academic machine learning model designed for cancer patients. We focused on this patient population because of their high short-term mortality risk and because we had access to the comparator model predictions. MATERIALS AND METHODS: This retrospective analysis included adult outpatients with metastatic cancer from four outpatient sites. Performance metrics included AUC for 1-year mortality and positive predictive value of high-risk score. RESULTS: There were 1,399 patients included. Median age at first EOLCI prediction was 67 and 55% were female. A total of 1,283 patients were evaluable for 1-year mortality
of these, 297 (23%) died within 1 year. AUC for 1-year mortality for EOLCI and academic model was 0.73 (95% CI [0.70-0.76]) and 0.82 (95% CI [0.80-0.85]), respectively. Positive predictive value was 0.38 and 0.65, respectively. CONCLUSION: The EOLCI's discrimination performance was lower than the vendor-stated value (AUC of 0.86) and the academic model's performance. Vendor-supplied machine learning models should be independently validated, particularly in specialized patient populations, to ensure accuracy and reliability.